BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17440963)

  • 1. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
    Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
    Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thapsigargin resistance in human prostate cancer cells.
    O'Neill JP; Velalar CN; Lee DI; Zhang B; Nakanishi T; Tang Y; Selaru F; Ross D; Meltzer SJ; Hussain A
    Cancer; 2006 Aug; 107(3):649-59. PubMed ID: 16770788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skp2 is associated with paclitaxel resistance in prostate cancer cells.
    Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J
    Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
    Kojima K; Fujita Y; Nozawa Y; Deguchi T; Ito M
    Prostate; 2010 Oct; 70(14):1501-12. PubMed ID: 20687223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
    Duan Z; Lamendola DE; Duan Y; Yusuf RZ; Seiden MV
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.
    Li L; Jiang AC; Dong P; Wang H; Xu W; Xu C
    Ann Surg Oncol; 2009 May; 16(5):1421-8. PubMed ID: 19247716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
    Li Y; Mizokami A; Izumi K; Narimoto K; Shima T; Zhang J; Dai J; Keller ET; Namiki M
    Prostate; 2010 Jan; 70(1):48-60. PubMed ID: 19725034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines.
    Podolski-Renić A; Andelković T; Banković J; Tanić N; Ruždijić S; Pešić M
    Biomed Pharmacother; 2011 Aug; 65(5):345-53. PubMed ID: 21775090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating multidrug resistance gene in leukaemia cells by short interfering RNA.
    Lim MN; Lau NS; Chang KM; Leong CF; Zakaria Z
    Singapore Med J; 2007 Oct; 48(10):932-8. PubMed ID: 17909680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids.
    Xing H; Wang S; Weng D; Chen G; Yang X; Zhou J; Xu G; Lu Y; Ma D
    Oncol Rep; 2007 Jan; 17(1):117-22. PubMed ID: 17143487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines.
    Machioka K; Izumi K; Kadono Y; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Keller ET; Zhang J; Mizokami A
    Oncotarget; 2018 Mar; 9(22):16185-16196. PubMed ID: 29662635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
    Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.
    Kato T; Fujita Y; Nakane K; Kojima T; Nozawa Y; Deguchi T; Ito M
    Biochem Biophys Res Commun; 2012 Jan; 417(3):966-71. PubMed ID: 22206665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
    Lee JT; Steelman LS; McCubrey JA
    Cancer Res; 2004 Nov; 64(22):8397-404. PubMed ID: 15548710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.